All News
NHANES Survey Shows OA Rising and RA Declining
An analysis of 43,706 adults from the 1999-2014 National Health and Nutrition Examination Surveys (NHANES) demonstrated temporal trends in the prevalence of arthritis, including a rise in osteoarthritis (OA) from 6.6% to 14.3%, while the prevalence of rheumatoid arthritis (RA) decreased from 5.9%
Read ArticleDMARDs Lower Dementia Risk in Rheumatoid Arthritis
UK researchers have analyzed rheumatoid arthritis (RA) patients from the UK Clinical Practice Research Database and shown that chronic conventional DMARD (cDMARD) use was associated with 40% lower risk of dementia (nearly 50% with methotrexate use).
Read ArticleRWCS Day 4 Podcast
Listen in on the proceedings from the 2018 RWCS meeting in Maui, with excerpts from leading teachers in rheumatology. This podcast features presentations from Drs.
Read ArticleThe RWCS - RheumNow Week in Review - 9 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes news and education from the RWCS meeting in Maui.
Read ArticleRWCS Day 2 Podcast
Listen in on the proceedings from the 2018 RWCS meeting in Maui with excerpts from leading teachers in rheumatology. This podcast features Drs. Martin Bergman, Jack Cush, Rachel Tate, Phil Aleksiejuk, Shubha Kollampare, Orrin Troum, and Alvin Wells. Listen here or on Stitcher, iTune, iPhone, Soundcloud or Google play.
Read ArticleRWCS Meeting Begins Today
The 11th annual meeting of the Rheumatology Winter Clinical Symposium (RWCS) begins today (2/7) and runs through Saturday (2/10) and features a premiere faculty delivering state-of-the-art lectures.
Read ArticleAbatacept Shows Promise for RA-ILD
Abatacept (Orencia) may be a useful treatment option for patients with rheumatoid arthritis (RA) who develop interstitial lung disease (ILD), a Spanish study suggested.
Read ArticleBiosimilar Reports - February 2018
Biosimilars command a great deal of research, development and attention given the promise of significant cost savings and potentially wider use for those in need. The global biosimilar market is expected to reach $36 billion USD by 2022. Here is this month's roundup of clinical trials and journal articles, overviews/reviews, practice and physician attitudes, and regulatory and pharma news - all on the subject of biosimilars.
Read ArticleMethotrexate May Help in Chronic Chikungunya Arthritis
Methotrexate may provide benefits in treatment of the chronic arthritis that can persist following acute chikungunya virus infection, but definitive evidence remains lacking, researchers reported.
Read ArticleThe RheumNow Week in Review - 2 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes rising epidemiologic numbers, vaccine updates for H.
Read ArticleLess Cardiovascular Risk with Abatacept in Rheumatoid Arthritis
A claims data analysis shows that abatacept use in rheumatoid arthritis (RA) patients yielded a modestly reduced cardiovascular risk when compared to patients receiving TNF inhibitors (TNFi).
Read Article15% of Users Exceed Recommended OTC NSAID Dosing
New data shows that nearly 15 percent of adult ibuprofen users exceed the maximum recommended dose of ibuprofen or other NSAIDs in a one-week period.
Read ArticleHigher Fracture Risk with PMR and GCA
Corticosteroid therapy is integral to the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) and a new retrospective cohort study from the UK shows that PMR and GCA have similar, increased risk of fractures.
Read ArticleThe RheumNow Week in Review - 26 January 2018
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report covers the price of biologics treatment in psoriasis, comorbidities in myositis, bronchiectasis with MPO antibodies, and the risk of secondary TNF failure with anti-drug antibodies.
Read ArticleAnti-Drug Antibodies Partly Explain Secondary TNF Inhibitor Failures
An observational study of patients with active rheumatoid arthritis (RA) or spondyloarthritis (SpA) experiencing secondary failure to TNF inhibitor (TNFi) therapy showed that (secondary) loss of efficacy to a TNFi was associated with anti-drug antibodies in less than 30% of patients.
Read ArticlePRESERVE Study: HAQ, BMI and Age Predict Responses to Combo Therapy
Rheumatoid arthritis patients who were younger and who had lower body mass index, Health Assessment Questionnaire (HAQ) scores, and less disease activity at baseline were most likely to achieve remission after combination etanercept (Enbrel) and methotrexate induction therapy, a post hoc analysis of the PRESERVE trial found.
Read ArticleTeriparatide Superior to Risedronate in the VERO Trial
Lancet reports that in a study teriparatide with risedronate, post-menopausal women with severe osteoporosis had significantly fewer new vertebral and clinical fractures on teriparatide comared to those receiving risedronate.
Read ArticleProblems with Biologic Drug Storage
Is your patient’s refrigerator the problem with the inefficacy of biologic therapies? Studies show most patients don't store their biologics correctly, which may be a source of limited drug efficacy.
Read ArticleWeight Loss Linked to RA Improvement
By retrospectively reviewing electronic health record (EHR) data, Kreps et al found that rheumatoid arthritis (RA) patients who lost >5 kg of weight were three times more likely to demonstrate improvement in disease activity.
Read ArticlePrevention of HBV Infection: How Are We Doing?
In 2016 the WHO set out to eliminate HBV infection as a public health threat by 2030. So far, we are far from this goal as vaccine implementation has been suboptimal in a number of important patient populations, including patients with rheumatologic diseases, as well as other immunocompromising diseases like HIV.
Read Article